Meinuo Weichuang Closed on a ￥10 Million Pre-A+ Financing Round

(VCBeat) Apr. 02, 2021 -- Meinuo Weichuang, a neurointerventional device developer, recently announced the completion of a Series Pre-A+ financing of nearly 10 million yuan, jointly invested by two funds of China Merchants Startup Capital. The funds raised will be used for product registration, purchasing of equipment and materials, team expansion, etc.

Prior to this, Meinuo Weichuang received tens of millions of yuan in the Pre-A investment round from Shanghai Chuangrui Investment Co., Ltd. in December 2020, and nearly ten million yuan of financing from Zhengxuan Fund of Shenzhen High-Tech Investment in May 2019.

Founded in 2017, Meinuo Weichuang is an innovative company focusing on the research, development, and production of neurointerventional instruments, aiming to benefit more domestic patients with cerebrovascular diseases through technological innovation. Its products include micro guidewires, microcatheters, coil springs, balloon catheters, cerebrovascular stents, thrombectomy devices and so on.

The core products of Meinuo Weichuang have achieved breakthroughs. Among them, the micro guidewire and microcatheter have obtained the registration certificate. Other product lines are currently in the development stage and are progressing well, with 2-3 products expected to be approved in 2021.

"The coil spring developed by Meinuo Weichuang can be electrically released in only 1 second compared to the mechanical released coil spring, and has lower propulsion resistance," said Wang Disi, the founder of Meinuo Weichuang.

There are also many innovations in the micro guide wires developed by Meinuo Weichuang. For example, its micro guide wire comes in four large sizes: 0.008 inch, 0.01 inch, 0.014 inch, and 0.018 inch. "The micro guide wire developed by Meinuo Weichuang with a diameter of 0.008 inches can reach the M3 and M4 regions of the brain, which has obvious advantages and fills the gap in China," Wang Disi said.

At present, Meinuo Weichuang has built an office of 300 square meters and a cleanroom of 13 million square meters. The company has also passed the verification of the Food and Drug Administration, to carry out mass production of products. This also means that the new forces in domestics represented by Meinuo Weichuang are emerging in the market, expanding the market with high-quality products and reasonable prices, improving the accessible rate of neurointerventional surgery, and benefiting more cerebrovascular disease patients.

China Merchants Startup Capital is an incubation and angel investment platform under China Merchants Venture. The company has built a three-wheel driving business model of "incubation + investment + fund management", and has gradually built an industrial investment ecosystem represented by "science and technology + financial services", "science and technology + traffic transportation", "science and technology + urban park" and "science and technology + big health".